Clinical trials in San Donato Milanese – page 131

2 835 clinical trials in San Donato Milanese, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

San Donato Milanese at a glance

2 835

clinical trials

Research sites1

Quick filters

2 835 trials in San Donato Milanese

Open in trial search

Cytomegalovirus immunisation

Not recruiting

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug

Italy

Participants:0–17 years · 18–64 years · Healthy volunteers
Substances:Sodium Chloride
Sponsor:Moderna Inc.

Contact Research Centre

Endometrial cancer recurrent

Not recruiting

A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy

Registered drugNo placebo

A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Paclitaxel
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Lung neoplasm malignant

Not recruiting

Evaluation of Pembrolizumab, Patritumab Deruxtecan, and Drug Combinations in Stage IV Non-Small Cell Lung Cancer: A Phase 2 Umbrella Study

Registered drugNo placebo

Evaluation of Pembrolizumab, Patritumab Deruxtecan, and Drug Combinations in Stage IV Non-Small Cell Lung Cancer: A Phase 2 Umbrella Study

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Plasma cell myeloma

Not recruiting

Efficacy and Safety Evaluation of Belantamab Mafodotin Versus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Registered drugNo placebo

Efficacy and Safety Evaluation of Belantamab Mafodotin Versus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Belantamab Mafodotin
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Chronic lymphocytic leukaemia+3

Not recruiting

Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

InvestigationalNo placebo

Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Nemtabrutinib
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Osteosarcoma

Not recruiting

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years
Substances:Cabozantinib
Sponsor:Ipsen Innovation

Contact Research Centre

Angelman's syndrome

Not recruiting

A Study Testing the Safety and How Well GTX-102 Works in Adults and Children with Angelman Syndrome

InvestigationalNo placebo

A Study Testing the Safety and How Well GTX-102 Works in Adults and Children with Angelman Syndrome

InvestigationalNo placebo

Italy

Participants:0–17 years · 18–64 years
Substances:Apazunersen
Sponsor:Ultragenyx Pharmaceutical Inc.

Contact Research Centre

Hormone-dependent prostate cancer+1

Not recruiting

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Enzalutamide
Sponsor:Pfizer Inc.

Contact Research Centre

Warm autoimmune haemolytic anaemia+1

Not recruiting

Study of ianalumab for adults with primary immune thrombocytopenia or warm-antibody autoimmune hemolytic anemia who previously responded to ianalumab

Registered drugNo placebo

Study of ianalumab for adults with primary immune thrombocytopenia or warm-antibody autoimmune hemolytic anemia who previously responded to ianalumab

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Danazol
Sponsor:Novartis Pharma AG

Contact Research Centre

Multiple sclerosis

Not recruiting

A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

Registered drugNo placebo

A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Ocrelizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

A study testing MK-1167 added to current treatment in patients with mild to moderate Alzheimer's disease dementia

Investigational

A study testing MK-1167 added to current treatment in patients with mild to moderate Alzheimer's disease dementia

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:MK-1167
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Prostate cancer

Not recruiting

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:Amgen Inc.

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in San Donato Milanese

What the registry says about research in the country

01 Gastroenterology Research

Leading studies focusing on inflammatory bowel diseases, including investigations of novel treatments for Crohn's Disease and Ulcerative Colitis. Research encompasses both established and experimental therapies aimed at inducing clinical remission.

Crohn's Disease Management
Ulcerative Colitis Treatments
Fecal Incontinence Therapy

Multiple trials evaluating innovative therapeutic approaches for gastrointestinal conditions.

02 Cardiovascular Studies

Comprehensive research into heart conditions, with particular emphasis on hypertrophic cardiomyopathy and heart failure. Studies evaluate new medications and surgical interventions.

Heart Failure Management
Cardiac Surgery Outcomes
Myocardial Infarction Research

Innovative approaches in treating various cardiac conditions using precision medicine techniques.

03 Immunology Research

Groundbreaking studies in hereditary angioedema and chronic urticaria, investigating both preventive treatments and acute attack management strategies.

Hereditary Angioedema Treatments
Chronic Urticaria Management
Pediatric Immunology Studies

Advanced therapeutic options being developed for rare immunological disorders.

Back to Italy All countries